Trial Profile

Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Leukemia

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19 chimeric antigen receptor T cell therapy Orgenesis (Primary) ; Antineoplastics
Indications B-cell leukaemia; Haematological malignancies
Focus Adverse reactions; Therapeutic Use
Sponsors Kecellitics Biotech

Most Recent Events

26 Nov 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2024.
26 Nov 2022 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2023.
26 Nov 2022 Planned initiation date changed from 1 Feb 2020 to 1 Feb 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com